Promising Clinical Progress for Tinlarebant
The Phase 3 DRAGON trial for Tinlarebant showed promising interim results with the DSMB recommending submission for further regulatory review. The trial is on track for completion by the end of the year.
Strong Financial Position
Belite Bio reported a cash increase of $12.3 million for the quarter, leaving the company with $157.4 million in cash and equivalents. The company expects a full year cash runway to complete all current clinical trials.
Phase 3 PHOENIX Trial Advancements
The PHOENIX trial for geographic atrophy has enrolled 464 subjects with a total target of 500. Enrollment is expected to be completed in Q3 2025.
Low Withdrawal Rates in Clinical Trials
DRAGON trial showed less than a 10% overall withdrawal rate, and the PHOENIX trial's dropout rate is approximately 20%, which is lower than comparables.